CN116034107A - 用作抗癌剂的奎宁环酮类似物 - Google Patents

用作抗癌剂的奎宁环酮类似物 Download PDF

Info

Publication number
CN116034107A
CN116034107A CN202180027033.3A CN202180027033A CN116034107A CN 116034107 A CN116034107 A CN 116034107A CN 202180027033 A CN202180027033 A CN 202180027033A CN 116034107 A CN116034107 A CN 116034107A
Authority
CN
China
Prior art keywords
methoxymethyl
hydroxymethyl
methyl
alkyl
quinuclidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027033.3A
Other languages
English (en)
Chinese (zh)
Inventor
陈怡�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newave Pharmaceutical Inc
Original Assignee
Newave Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newave Pharmaceutical Inc filed Critical Newave Pharmaceutical Inc
Publication of CN116034107A publication Critical patent/CN116034107A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180027033.3A 2020-02-09 2021-02-05 用作抗癌剂的奎宁环酮类似物 Pending CN116034107A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062972002P 2020-02-09 2020-02-09
US62/972,002 2020-02-09
US202063002106P 2020-03-30 2020-03-30
US63/002,106 2020-03-30
US202063019374P 2020-05-03 2020-05-03
US63/019,374 2020-05-03
US202063053592P 2020-07-18 2020-07-18
US63/053,592 2020-07-18
PCT/US2021/016862 WO2021158948A1 (en) 2020-02-09 2021-02-05 Quinuclidinone analogues as anticancer agents

Publications (1)

Publication Number Publication Date
CN116034107A true CN116034107A (zh) 2023-04-28

Family

ID=74860395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027033.3A Pending CN116034107A (zh) 2020-02-09 2021-02-05 用作抗癌剂的奎宁环酮类似物

Country Status (5)

Country Link
US (1) US20230089530A1 (https=)
EP (1) EP4100407A1 (https=)
JP (1) JP2023514188A (https=)
CN (1) CN116034107A (https=)
WO (1) WO2021158948A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175402A1 (en) * 2021-02-18 2022-08-25 Aprea Therapeutics Ab Quinuclidine-3-one derivatives
PY2217419A (es) 2021-03-15 2022-09-27 Novartis Ag Derivados de pirazolopiridina y sus usos
WO2022204109A1 (en) * 2021-03-22 2022-09-29 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781447A (zh) * 2010-01-21 2012-11-14 阿普里有限公司 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781447A (zh) * 2010-01-21 2012-11-14 阿普里有限公司 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QIANG ZHANG，ET AL.: "APR-246 reactivates mutant p53 by targeting cysteines 124 and 277", CELL DEATH AND DISEASE, vol. 9, 31 December 2018 (2018-12-31), pages 439 *
VLADIMIR J.N. BYKOV, ET AL.: "Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound", NATURE MEDICINE, vol. 8, no. 3, 31 March 2002 (2002-03-31), pages 282 - 288, XP002979239, DOI: 10.1038/nm0302-282 *

Also Published As

Publication number Publication date
JP2023514188A (ja) 2023-04-05
EP4100407A1 (en) 2022-12-14
US20230089530A1 (en) 2023-03-23
WO2021158948A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
US11236089B2 (en) Substituted pyrrolopyridines as ATR inhibitors
US12569564B2 (en) Spirocyclic MDM2 modulator and uses thereof
WO2022271823A1 (en) Mutant kras modulators and uses thereof
EP3672976B1 (en) Bcl-2 inhibitors
WO2025059040A1 (en) Mutant kras modulators and uses thereof
WO2023137223A1 (en) Pan-kras inhibitors and uses thereof
US10253029B2 (en) Dual-warhead covalent inhibitors of FGFR-4
CN116034107A (zh) 用作抗癌剂的奎宁环酮类似物
CA3131517A1 (en) Inhibitor of btk and mutants thereof
WO2015050703A1 (en) Inhibitors of bruton's tyrosine kinase
US20250136620A1 (en) Btk degrader
US20250099481A1 (en) Bcl-2 inhibitors
US12552784B2 (en) 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CA3120941A1 (en) Orally active prodrug of gemcitabine
US20240390368A1 (en) Inhibitor of btk and mutants thereof
US20240217964A1 (en) Quinuclidinone analogues as anticancer agents
US20250177429A1 (en) Orally active prodrug of gemcitabine
WO2023230059A1 (en) Mdm2 degrader
US20250145639A1 (en) Mutant kras modulators and uses thereof
WO2023283130A1 (en) Isoquinoline derivatives as mutant egfr modulators and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230428

WD01 Invention patent application deemed withdrawn after publication